Open AccessClinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial
Author(s) -
Jared M. Baeten,
Stewart E. Reid,
Sinéad Delany-Moretlwe,
James P. Hughes,
Richard S. Wang,
Ellen Wilcox,
Mohammed Limbada,
Godspower Akpomiemie,
Lawrence Corey,
Anna Wald,
Connie Celum
Publication year - 2012
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0b013e31823b50c6
Subject(s) - medicine , placebo , herpes genitalis , herpes simplex virus , randomized controlled trial , lesion , aciclovir , sex organ , gastroenterology , immunology , viral disease , surgery , human immunodeficiency virus (hiv) , herpesviridae , virus , genital herpes , pathology , biology , genetics , alternative medicine
In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).